{"companyId":78597,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","ja"],"companyName":"Gyre Therapeutics, Inc.","headOfficeLocation":"Seattle, Washington, USA","presidentName":"Ruoyu Chen","companySummary":null,"stockCode":"GYRE","currency":null,"capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["gyretx.com"],"businessContents":["Drug development for organ fibrosis","Pirfenidone-based therapy for Idiopathic Pulmonary Fibrosis","Targeted protein degrader and degrader-antibody conjugate therapies for cancer and inflammatory dise"],"relations":[{"detailNumber":1,"relationCompanyName":"Cullgen Inc.","relationCompanyId":78599,"url":null,"linkUrl":null,"remarks":null,"lastCheckDate":"2026-04-27","raGroup":70,"raParent":0,"raChild":70,"raCustomer":0,"raSupplier":0,"raPartnership":0,"raFinance":0,"raInvest":0}],"dataSources":[{"detailNumber":1,"url":"https://www.gyretx.com/about/","scoreAbout":68,"scoreBusiness":11,"scoreGroup":11,"scoreCustomer":3},{"detailNumber":2,"url":"https://www.gyretx.com/","scoreAbout":50,"scoreBusiness":16,"scoreGroup":11,"scoreCustomer":3}]}